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1. Introduction 
Hypothyroidism is the most common disorder of thyroid dysfunction. Sometimes, it can be 
caused by a variety of medical treatments that leads to a decrease in thyroidal production 
and secretion of thyroxine and triiodothyronine. Radiation treatment, either radioactive 
iodine treatment of hyperthyroidism or external radiation treatment for cancer therapy is a 
major cause of treatment related hypothyroidism. Others include various drugs associated 
with thyroid suppression, include lithium, iodine, iodine-containing drugs, radiographic 
contrast agents and cytotoxic chemotherapy. Thyroid dysfunction is one of the most 
common complications in endocrine system after hematological stem cell transplantation. 
This chapter will discuss certain type of primary hypothyroidism, including those 
encountered commonly in clinical practice, such as radioactive iodine therapy, tyrosine 
kinase inhibitor, hematological stem cell transplantation or other entities.  
2. Causes of treatment related hypothyroidism 
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Fig. 1. Causes of treatment-related hypothyroidism 
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2.1 Hypothyroidism due to thyroid ablation 
Radioactive iodine therapy 
Thyroid ablation using radioactive iodine for thyroid cancer is one of the most common 
causes of nonspontaneous hypothyroidism since the treatment modality is an important 
step in adjuvant or palliative setting of thyroid cancer. Radioactive iodine is an effective 
agent for delivering high radiation doses to the thyroid tissue with low spillover to other 
portions of the body. The radiation dose to the thyroid tissue is related to the tissue 
concentration, the ratio between the total tissue uptake and the volume of functional tissue, 
and the effective half-life of radioactive iodine in the tissue. Radioactive iodine therapy 
generally results in hypothyroidism, necessitating levothyroxine treatment. In thyroid 
cancer, total ablation of thyroid function can be achieved after administration of either 
100 mCi or 30 mCi in more thane 80% of patients who had at least a near-total 
thyroidectomy. After less extensive surgery, ablation can be achieved in only two thirds of 
patients with 30 mCi. 
External radiotherapy 
Radiotherapy is a frequently applied treatment in patients with head and neck cancer, and 
sometimes in patients with inoperative thyroid cancer as well as lymphoma. Despite its 
beneficial effects on locoregional tumor control, radiation may also cause a variety of acute 
or late side effects, which may be progressive and hamper health-related quality of life 
(Langendijk et al. 2008). Hypothyroidism may develop within the first year after 
radiotherapy, especially in patients under 20 years of age. After external radiotherapy, 
hypothyroidism develops at a median interval of 1.4-1.8 (range 0.3-7.2) years, but may 
continue to develop many years following therapy (Mercado et al. 2001; Tell et al. 2004). 
Approximately 30% of patients with solid tumors of the head and neck cancer treated with 
external radiotherapy develop hypothyroidism (Tami et al. 1992). In stem cell 
transplantation, hypothyroidism occurs in approximately 9% to 16 % of adults who undergo 
total body irradiation (Al-Fiar et al. 1997). From a 30 years’ experience at the Fred 
Hutchinson Cancer Research Center in treating children with stem cell transplantation, 
hypothyroidism is the most common type of thyroid dysfunction as 30% developed 
hypothyroidism at various times after stem cell transplantation. The incidence of 
hypothyroidism increased with total body irradiation and the use of busulfan-based 
regimen (Sanders et al. 2009). 
2.2 Hypothyroidism due to therapeutic pharmacological agents 
Several drugs can cause hypothyroidism by interfering with thyroid hormone production or 
provoking thyroid autoimmunity. Pharmacological iodine, such as those to which patients 
treated with amiodarone or other iodine-containing compounds are exposed, can inhibit 
thyroid hormone production, especially when combined with underlying autoimmune 
thyroiditis, and cause hypothyroidism.  
Amiodarone 
Amiodarone is a commonly prescribed anti-arrhythmic drug because of its ability to treat 
various types of cardiac arrhythmia including ventricular arrhythmia, paroxysmal 
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supraventricular tachycardia, atrial fibrillation and flutter with minimal negative inotropic 
and proarrhythmic effects. It is benzofuran derivative containing 37.5% iodine by weight. 
Daily maintenance dosages of 100 to 600 mg result in a 35 to 140 fold excess in 
recommended daily iodine intake of 100 to 150 µg. Such a high iodine content and inherent 
effects of amiodarone and its active metabolite desethylamiodarone are postulated to result 
in thyroid dysfunction in 14 to 18 % subjects after 2 to 3 years of treatment (Martino et al. 
2001). Amiodarone induced hypothyroidism is due to the inhibition of iodine oxidation 
because of excess intrathyroidal iodine, which is known as the Wolff-Chaikoff effect (Eng et 
al. 1999). In addition to iodine related effects, amiodarone can alter the activity of deiodinase 
enzymes. The inhibition of iodothyronine deiodinase activity in peripheral tissues results in 
decreased triiodothyronine concentration, increased total thyrosine concentration and 
increased reverse triiodothyronine concentration in serum (Martino et al. 2001). Whether to 
discontinue amiodarone is still controversial. Withdrawal of the drug may precipitate 
dysrhythmia, especially as most other alternative anti-arrhythmics are seldom as effective. 
The treatment of choice for amiodarone induced hypothyroidism is levothyroxine. 
Amiodarone can be continued at discretion of the cardiologist, keeping in mind that 
spontaneous remission of hypothyroidism may occur. If amiodarone treatment is 
discontinued, the decision to initiate thyroid hormone replacement can be delayed (Cohen-
Lehman et al. 2010). 
Lithium  
One in 200 people receives lithium for treatment of bipolar disorder. Lithium has many 
actions on thyroid physiology. The most important clinical relevant action is the inhibition 
of thyroid hormone release. The effect of lithium on inhibition of cyclic AMP-mediated 
cellular events and its inhibitory effect on the phosphoinositol pathway help to explain the 
intracellular disturbances, but the full mechanism is still not clear. The immunological 
influence of lithium on thyroid antibody concentrations leads to a more rapid onset of 
thyroid autoimmunity characterized usually by goiter and hypothyroidism. The clinical side 
effects of the drug are goiter in up to 40% and hypothyroidism in about 20% (Lazarus 2009). 
Treatment of lithium-induced hypothyroidism with levothyroxine is no different from 
treatment of primary hypothyroidism. In these cases there is often a concern that even mild 
hypothyroidism may contribute to depressive symptoms and that increased thyroid 
stimulating hormone levels may favor further growth of goiter. The presence of thyroid 
abnormalities alone is almost never a reason for lithium discontinuation, as this medication 
is often crucial in maintaining these patients free of the most severe manifestations of their 
psychiatric illness (Barbesino 2010). 
Interferon alpha 
Interferon alpha is used for the treatment of hepatitis B and C, as well as various 
neoplasms, including malignant carcinoid, Kaposi’s sarcoma and hairy cell leukemia. 
Dose-limited side effects of interferon alpha are common, most frequently malaise, 
depression and hematological side effects. Thyroid dysfunction during interferon alpha is 
also quite common. Hypothyroidism was initially described as a side effect of interferon 
alpha therapy in patients receiving long-term interferon alpha treatment for breast cancer 
(Fentiman et al. 1985). Thyroid effects of interferon alpha have been classified as 
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autoimmune and nonautoimmune, mostly based on the presence or absence of markers of 
thyroid autoimmunity such as serum thyroid peroxidase and / or thyroglobulin 
antibodies (Mandac et al. 2006). The observed incidence of interferon alpha associated 
hypothyroidism in patients with hepatitis C has been reported from approximately 6% to 
10% (Deutsch et al. 1997; Koh, Greenspan, and Yeo 1997). Transient hypothyroidism 
occurs more commonly with interferon alpha therapy than does persistent 
hypothyroidism, although pooled data from several series indicates that 30% to 44% of 
patients who develop hypothyroidism during interferon alpha treatment develop 
persistent thyroid failure (Preziati et al. 1995).  
Interleukin-2 
Interleukin-2 is used in the treatment of melanoma and renal cell carcinoma. In one series, 
32% of 111 patients with cancer developed hypothyroidism during interleukin-2 treatment, 
and 14% had hypothyroidism postimmunotherapy, persisting from 44 to greater than 149 
days (Schwartzentruber et al. 1991). Earlier studies showed a higher incidence of 
hypothyroidism up to 21% after treatment of interleukin-2 in combination with lymphokine-
activated killer cells (Atkins et al. 1988). Most patients who developed hypothyroidism had 
positive thyroglobulin or thyroid peroxidase antibodies, suggesting autoimmune 
thyroiditis. Similarly to interferon alpha-induced thyroid disorders, hypothyroid patients 
are easily treated with thyroid hormone, while destructive thyrotoxicosis only requires 
symptom control with beta-blockers. 
Tyrosine kinase inhibitors 
Tyrosine kinase inhibitors have recently emerged as promising chemotherapeutic agents in 
several types of malignant neoplasms, including thyroid cancer. Several tyrosine kinase 
inhibitors exert distinctive effects on thyroid function. Tyrosine kinase inhibitors affect 
thyroid function through two major mechanisms: by increasing thyroid hormone 
requirements in patients on thyroid hormone replacement and by causing primary 
hypothyroidism in patients with previously normal thyroid function. In a small clinical 
report, imatinib caused a fourfold increase in thyroid stimulating hormone level in all eight 
patients taking levothyroxine after total thyroidectomyt for medullary thyroid cancer. The 
effect was reversible after discontinuation of treatment and it could be corrected by a 
doubling in the daily levothyroxine dosage in some patients. There was no change in total 
thyroxine to suggest increased serum protein binding of thyroid hormone as a possible 
explanation. Hence, these effects of imatinib are most likely related to increase liver 
metabolism of thyroid hormone (Barbesino 2010; de Groot et al. 2005). Sunitinib is an oral, 
multitargeted tyrosine kinase inhibitor of vascular growth receptors, stem cell factor 
receptor and platelet-derived growth factor receptors. It has been approved for the 
treatment of gastrointestinal stromal tumor and metastatic renal cell carcinoma. 
Hypothyroidism has been observed as an adverse event and a clinically relevant toxicity of 
sunitinib. In one study, 36% of patients with gastrointestinal stromal tumor treated with 
sunitinib, developed primary hypothyroidism (Desai et al. 2006). Rini et al reported that 
hypothyroidism occurred in 56 (85%) of 66 patients with metastatic renal cell carcinoma 
(Rini et al. 2007). Although the mechanism behind this complication remains unclear, it is 
considered that treatment with levothyroxine can control subclinical and overt 
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hypothyroidism. There have been cases of thyroid atrophy following sunitinib treatment, 
suggesting a direct effect of sunitinib that leads to degeneration of thyroid follicular cells 
(Shinohara et al. 2011). 
Cytotoxic chemotherapy 
Cytotoxic chemotherapy can alter thyroid function in a small proportion of patients. An 
increased incidence of primary hypothyroidism has been documented in patients treated 
with multiple drug regimens (Yeung et al. 1998). There is some evidence that L-asparaginase 
can cause pituitary hypothyroidism, which is resulted from reducing the thyroid 
stimulating hormone response to thyroid releasing hormone (Heidemann, Stubbe, and Beck 
1981). In patients with testicular cancer who received combinations of cisplatin, bleomycin, 
vinblastine, etoposide, and dactinomycin, 4 of 27 individuals (15%) developed 
hypothyroidism. In particular, the cumulative doses of cisplatin and vincristine seem to 
exacerbate these symptoms (Stuart et al. 1990). Forty-four percent of patients who received 
six cycles of MOPP regimen (mechlorethamine, vinblastine, procarbazine, and 
prednisolone) for Hodgkin’s disease developed an elevated serum thyroid stimulating 
hormone concentration (Sutcliffe, Chapman, and Wrigley 1981).  
2.3 Hypothyroidism after hematopoietic stem cell transplantation 
Thyroid dysfunction is an important problem in patents receiving hematopoietic stem cell 
transplantation and several forms of thyroid disorders have been reported including 
hypothyroidism, euthyroid sick syndrome, transfer of autoimmune thyroiditis, graft-versus-
host disease, and secondary thyroid tumors (Kami et al. 2001). Hypothyroidism is one of the 
common forms of thyroid disorder after hematopoietic stem cell transplantation. Its 
frequency was found to be as high as 40% (Borgstrom, and Bolme 1994; Sklar, Kim, and 
Ramsay 1982) and it appeared to increase with the duration of post-transplant follow-up. In 
less common instance, patients appeared to have hyperthyroidism after stem cell 
transplantation, even six months later from clinical reports (Feng et al. 2008). Development 
of hypothyroidism has been attributed largely to exposure to radiation (Sanders 1990), but it 
also does occur after chemotherapy-based preparative regimens.  
Mechanism of thyroid dysfunction after hematopoietic stem cell transplantation 
Hematopoietic stem cell transplantation is a potentially curative procedure for a variety of 
malignant and non-malignant conditions. When developed initially, hematopoietic stem cell 
transplantation was considered an approach to rescue patients from toxic side effects of 
supralethal doses of radiation and chemotherapy used to treat various underlying diseases 
by transplanting hematopoietic stem cells, which had the ability to reconstitute 
hematopoiesis. In allogeneic hematopoietic stem cell transplantation, healthy hematopoietic 
stem cell s are harvested from a separate, related or unrelated, ideally human leukocyte 
antigen-matched donor, and used to replace the patient’s own abnormal hematopoietic stem 
cells. Conditioning regimen for allogeneic hematopoietic stem cell transplantation often 
combine total body irradiation and high-dose chemotherapy to eradicate the patient’s 
malignant cell population at the cost of partial or complete bone marrow ablation. 
Autologous hematopoietic stem cell transplantation requires the extraction of hematopoietic 
stem cells from the patient. The harvested hematopoietic stem cells return to the patient’s 
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body to resume normal blood cell production after conditioning treatment. Individuals 
successfully treated with hematopoietic stem cell transplantation are at risk of developing 
post-transplant complications as a result of drug and radiation toxicity, as are those treated 
with allogeneic hematopoietic stem cell transplantation as a consequence of graft versus 
host disease. Endocrine complications are among the most prevalent late effects observed in 
hematopoietic stem cell transplantation recipients (Chemaitilly, and Sklar 2007; Hows et al. 
2006). Several thyroid abnormalities have been described following hematopoietic stem cell 
transplantation. These include therapy-induced primary hypothyroidism, autoimmune 
thyroid disease, and thyroid neoplasms. 
Autologous hematopoietic stem cell transplantation 
Autologous hematopoietic stem cell transplantation is performed more frequently than any 
allogeneic type of organ transplantation worldwide. The endocrine system is one of the 
most common targets of post-transplant complications. The relative risk of developing 
endocrine disorders was found to be related to underlying diseases, previous treatments, 
use of radiation therapies and type of irradiation schedule, post-transplant treatment and 
age (Brennan, and Shalet 2002; Shalet et al. 1995). Carlson et al. described hypothyroidism 
developed in 20 of 111 (18%) individuals after autologous stem cell transplantation and the 
incidence of hypothyroidism was more frequent in patients treated with total body 
irradiation (Carlson et al. 1992). There were some reports on development of 
hypothyroidism after non-total body irradiation preparative regimens (Michel et al. 1997; 
Toubert et al. 1997). Considering the wide differences in the total doses of radiation applied, 
during treatment of Hodgkin’s disease versus preparative conditioning for hematopoietic 
stem cell transplantation, the incidence of hypothyroidism after hematopoietic stem cell 
transplantation remains striking. These findings suggest that irradiation of the thyroid gland 
may not be the sole cause of hypothyroidism after hematopoietic stem cell transplantation. 
Early effect of thyroid dysfunction was reported by Tauchmanova in patients first year after 
autologous hematopoietic stem cell transplantation. Subclinical hypothyroidism was 
diagnosed in 10% of patients and worsened progressively in all but one patient 
(Tauchmanova et al. 2005).  
Allogeneic hematopoietic stem cell transplantation 
Hypothyroidism haven been reported to be as high as 52% of patients with allogeneic 
hematopoietic stem cell transplantation (Al-Hazzouri et al. 2009; Bailey et al. 2008; Berger et 
al. 2005; Sanders et al. 2009). The time course of developing hypothyroidism after 
hematopoietic stem cell transplantation varied based on the conditioning regimen. In one 
study, patients who received single fraction total body irradiation developed compensated 
hypothyroidism at a mean of 3.2 (range 1-8.2) years after hematopoietic stem cell 
transplantation and progressed to overt hypothyroidism about 1-2 years later (Thomas et al. 
1993). Hypothyroidis was recognized between 0.9 and 7.3 (median 4.1) years after 
hyperfractionated radiation and at a median of 4.2 years in patients conditioned with 
busulfan and cyclophosphamide (Boulad et al. 1995). In a 30 year-surveillance of post-
transplant, 30% of children developed hypothyroidism at various times after hematopoietic 
stem cell transplantation and among these 20% were treated with thyroid hormone. Thyroid 
dysfunction continues to occur as long as 28 years after hematopoietic stem cell 
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transplantation conditioning with total body irradiation and as long as 10 years after 
busulfan-cyclophosphamide preparative regimen (Sanders et al. 2009).  
The mechanism for hypothyroidism after transplant is unknown. Donor antibody transfers, 
immune-mediated injury, conditioning treatment effects, post-transplant medications and 
patient susceptibility may play a role in post-hematopoietic stem cell transplantation 
hypothyroidism. Case studies have shown that a donor with autoimmune thyroid disorder 
may transfer cell capable of injuring the recipient’s thyroid gland after hematopoietic stem cell 
transplantation (Lee et al. 2001; Marazuela, and Steegman 2000). Immune-mediated thyroid 
injury arising in the host has been suggested in other studies and may be a form of graft-
versus-host-disease (Kami et al. 2001; Katsanis et al. 1990; Somali et al. 2005). Patients receiving 
single-agent graft-versus-host-disease prophylaxis were found to have a 9.5 times greater risk 
of developing hypothyroidism than patients with multi-agent prophylaxis (Katsanis et al. 
1990). From an immunological standpoint, stem cells from matched sibling donors are though 
to be less immunologically reactive than those from unrelated donors. Patients who received 
stem cells from an unrelated donor had over an eightfold increased risk of hypothyroidism 
compared to those who received matched sibling stem cells (Bailey et al. 2008). Total body 
irradiation is a well established risk factor for hypothyroidism after hematopoietic stem cell 
transplantation and used of fractionated instead of single-dose total body irradiation decreases 
its risk (Boulad et al. 1995). Other risk factor for developing hypothyroidism after 
hematopoietic stem cell transplantation includes young age at transplantation and stem cell 
transplantation during second complete remission (Berger et al. 2005; Ishiguro et al. 2004). A 
study focused on reduced-intensity conditioning regimen in hematopoietic stem cell 
transplantation disclosed that the incidence of post-transplant hypothyroidism was similar in 
myeloablative or reduced-intensity conditioning regimen (Al-Hazzouri et al. 2009). 
3. Conclusions 
The endocrine system is one of the most common targets of post-treatment complications in 
cancer survivors. The relative risk of developing endocrine disorders was found to be 
related to underlying diseases, previous treatments, use of radiation therapies, and post-
transplant treatments. Thyroid dysfunction has been frequently reported after 
hematopoietic cell transplantation. Radiation has been considered the main cause for this 
and for thyroid malignancies, but in the context of hematopoietic cell transplantation, total 
body irradiation has been considered to be the major cause. The incidence of post-transplant 
thyroid disorder ranging from 0% to 57% was reported previously. Sick euthyroid 
syndrome was more frequently observed. Most patients developed a mild compensated 
primary hypothyroidism that may be transient and can be resolved spontaneously. 
Hypothyroidism can be an early complication but is usually considered as a late 
complication identified several years after hematopoietic cell transplantation. 
Approximately 15 % of patients develop overt primary hypothyroidism and 30% have 
compensated hypothyroidism. The incidence is lower in patients treated with autologous 
hematopoietic cell transplantation or conditioned with chemotherapy alone.  
With the cumulative experiences in hematopoietic cell transplantation and advances in 
supportive care, the number of long-term survivors has increased. Knowledge about 
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increased risk for long term complications due to cancer therapy and pre-hematopoietic cell 
transplantation preparative regimen should encourage each physician to improve their 
quality of care. 
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